Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.

Čájet eará veršuvnnaid (1)

OBJECTIVE: To evaluate the safety and efficacy of a chimeric monoclonal antibody to tumor necrosis factor alpha (TNF alpha) in the treatment of patients with rheumatoid arthritis (RA). METHODS: Twenty patients with active RA were treated with 20 mg/kg of anti-TNF alpha in an open phase I/II trial la...

Bibliográfalaš dieđut
Váldodahkkit:	Elliott, M, Maini, R, Feldmann, M, Long-Fox, A, Charles, P, Katsikis, P, Brennan, F, Walker, J, Bijl, H, Ghrayeb, J
Materiálatiipa:	Journal article
Giella:	English
Almmustuhtton:	1993

Geahča maid

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
Dahkki: Elliot, M, et al.
Almmustuhtton: (2008)

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis.
Dahkki: Elliott, M, et al.
Almmustuhtton: (1994)

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis.
Dahkki: Elliott, M, et al.
Almmustuhtton: (1994)

Selective immunosuppression of tumour necrosis factor-alpha in rheumatoid arthritis.
Dahkki: Brennan, F, et al.
Almmustuhtton: (1995)

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis.
Dahkki: Paleolog, E, et al.
Almmustuhtton: (1996)

TNF alpha as a therapeutic target in rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1994)

Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA)
Dahkki: Maini, R, et al.
Almmustuhtton: (1995)

Anti-tumor necrosis factor-alpha therapy of rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1997)

Use of anti-tumor necrosis factor antibodies in rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1994)

Anti-tumor necrosis factor alpha therapy of rheumatoid arthritis. Mechanism of action.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1997)

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
Dahkki: Maini, R, et al.
Almmustuhtton: (1999)

Targeting TNF alpha for the therapy of rheumatoid arthritis.
Dahkki: Maini, R, et al.
Almmustuhtton: (1994)

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis.
Dahkki: Maini, R, et al.
Almmustuhtton: (1998)

Anaemia of chronic disease in rheumatoid arthritis: in vivo effects of tumour necrosis factor alpha blockade.
Dahkki: Davis, D, et al.
Almmustuhtton: (1997)

Evaluation of the role of cytokines in autoimmune disease: the importance of TNF alpha in rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1992)

TNF alpha is an effective therapeutic target for rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1995)

Monoclonal anti-TNF alpha antibody as a probe of pathogenesis and therapy of rheumatoid disease.
Dahkki: Maini, R, et al.
Almmustuhtton: (1995)

Immunological intervention reveals reciprocal roles for tumor necrosis factor-alpha and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus.
Dahkki: Maini, R, et al.
Almmustuhtton: (1994)

Immunoregulatory role of interleukin 10 in rheumatoid arthritis.
Dahkki: Katsikis, P, et al.
Almmustuhtton: (1994)

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis.
Dahkki: Tak, P, et al.
Almmustuhtton: (1996)

TNF alpha--a pivotal role in rheumatoid arthritis?
Dahkki: Brennan, F, et al.
Almmustuhtton: (1992)

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha.
Dahkki: Haworth, C, et al.
Almmustuhtton: (1991)

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials.
Dahkki: Charles, P, et al.
Almmustuhtton: (2000)

Similarities in the mechanisms of action of pulse corticosteroids and anti-tumor necrosis factor alpha therapy in rheumatoid arthritis - Reply
Dahkki: Maini, R, et al.
Almmustuhtton: (1998)

The role of TNF alpha and IL-1 in rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (2001)

What is the mechanism of action of anti-tumour necrosis factor-alpha antibody in rheumatoid arthritis?
Dahkki: Feldmann, M
Almmustuhtton: (1996)

Cytokine expression and networks in rheumatoid arthritis: rationale for anti-TNF alpha antibody therapy and its mechanism of action.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1995)

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis.
Dahkki: Taylor, P, et al.
Almmustuhtton: (2000)

Anti-tumour necrosis factor specific antibody (infliximab) treatment provides insights into the pathophysiology of rheumatoid arthritis.
Dahkki: Maini, R, et al.
Almmustuhtton: (1999)

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis.
Dahkki: Chu, C, et al.
Almmustuhtton: (1991)

Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis. Implications for local actions of tumor necrosis factor alpha.
Dahkki: Deleuran, B, et al.
Almmustuhtton: (1992)

TNF-alpha in rheumatoid arthritis and prospects of anti-TNF therapy.
Dahkki: Maini, R, et al.
Almmustuhtton: (1993)

TNF alpha blockade in rheumatoid arthritis: rationale, clinical outcomes and mechanisms of action.
Dahkki: Elliott, M, et al.
Almmustuhtton: (1995)

Reduction of serum matrix metalloproteinase 1 and matrix metalloproteinase 3 in rheumatoid arthritis patients following anti-tumour necrosis factor-alpha (cA2) therapy.
Dahkki: Brennan, F, et al.
Almmustuhtton: (1997)

Rheumatoid arthritis.
Dahkki: Feldmann, M, et al.
Almmustuhtton: (1996)

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis.
Dahkki: Brennan, F, et al.
Almmustuhtton: (1989)

Localization of interleukin-1 alpha, type 1 interleukin-1 receptor and interleukin-1 receptor antagonist in the synovial membrane and cartilage/pannus junction in rheumatoid arthritis.
Dahkki: Deleuran, B, et al.
Almmustuhtton: (1992)

Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures. Comparison of monoclonal anti TNF-alpha antibody with the interleukin-1 receptor antagonist.
Dahkki: Butler, D, et al.
Almmustuhtton: (1995)

Systemic anti-tumor necrosis factor alpha therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor alpha synthesis.
Dahkki: Ulfgren, A, et al.
Almmustuhtton: (2000)

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis.
Dahkki: Paleolog, E, et al.
Almmustuhtton: (1998)